Featured News

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

Austin, Texas, USA, March 31, 2021 — Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

 

“We are excited to offer our unique set of tools and services to collaborators such as argenx to assist with their autoimmune therapy programs,” said Pure MHC President Kris Looney, “Pure MHC Solutions is uniquely positioned to provide access to these tools and has the deep HLA
expertise that we believe will help drive better outcomes not only for our partners, but ultimately, for their patients.”

Other News

Austin, Texas, USA Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx

March 31, 2021

Austin, Texas, USA — Pure MHC, LLC, a target discovery and development
company, today announced the launch of its Peptide HLA Immunotherapy Data Resource
(“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a
leader in regenerative medicine, LifeNet Health.

March 16, 2021

OKLAHOMA CITY, OK AND AUSTIN, TX – The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.

March 20, 2020

Emergent Technologies, Inc. (ETI) announced today that Steven Lloyd Mayer, MD has been hired as Chief Medical Officer to support commercialization efforts for its portfolio companies Pure MHC, LLC and Caisson Biotech, LLC . . .

February 13, 2019

Emergent Technologies, Inc. (ETI) announced today that its target discovery portfolio company, Pure MHC, and global biopharmaceutical company, AbbVie (NYSE:ABBV) will embark on a research and license agreement to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancers.
January 09, 2017

Emergent Technologies, Inc. announced today that its portfolio company,
Receptor Logic, has entered into an exclusive License Agreement with Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for autoimmune diseases, asthma and
allergic diseases, and cancer.

January 12, 2016

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC)
announced an agreement with Pure MHC, an Emergent Technologies portfolio
company, for development of a novel assay for quality control that will be an
important component of ImmunoCellular’s ICT-107 phase 3 registrational
clinical program in newly diagnosed glioblastoma, anticipated to begin in the
second half of 2015.

June 22, 2015

A recent cancer study performed by the Washington University School of
Medicine in St. Louis has garnered significant interest from the science and
medical community. This research, led by Dr. Beatriz Carreno, tested the
ability of a personalized cancer vaccine to assist the immune system’s
effectiveness in attacking a patient’s specific tumor.

April 1, 2015

PhosImmune Inc. and PureMHC LLC today announced they have entered into a
license and collaboration agreement to develop novel antibody-based
immunotherapies designed to target cancers.

October 21, 2014